Armistice Capital Upped By $364,000 Its Alimera Sciences (ALIM) Position; Columbia Wanger Asset Management Boosted Dorman Products (DORM) Position

January 14, 2018 - By Ellis Scott

Columbia Wanger Asset Management Llc increased Dorman Products Inc (DORM) stake by 26.88% reported in 2017Q3 SEC filing. Columbia Wanger Asset Management Llc acquired 55,208 shares as Dorman Products Inc (DORM)’s stock rose 14.29%. The Columbia Wanger Asset Management Llc holds 260,573 shares with $18.66M value, up from 205,365 last quarter. Dorman Products Inc now has $2.41B valuation. The stock increased 1.07% or $0.76 during the last trading session, reaching $71.74. About 165,407 shares traded. Dorman Products, Inc. (NASDAQ:DORM) has risen 57.51% since January 14, 2017 and is uptrending. It has outperformed by 40.81% the S&P500.

Armistice Capital Llc increased Alimera Sciences Inc (ALIM) stake by 6.17% reported in 2017Q3 SEC filing. Armistice Capital Llc acquired 364,000 shares as Alimera Sciences Inc (ALIM)’s stock rose 22.95%. The Armistice Capital Llc holds 6.26M shares with $8.46 million value, up from 5.90M last quarter. Alimera Sciences Inc now has $88.51M valuation. It closed at $1.28 lastly. It is up 0.67% since January 14, 2017 and is uptrending. It has underperformed by 16.03% the S&P500.

Among 8 analysts covering Dorman Products (NASDAQ:DORM), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Dorman Products had 17 analyst reports since October 14, 2015 according to SRatingsIntel. The rating was downgraded by BB&T Capital to “Hold” on Thursday, October 15. The rating was maintained by FBR Capital with “Outperform” on Thursday, October 29. As per Wednesday, January 4, the company rating was downgraded by CL King. Jefferies maintained Dorman Products, Inc. (NASDAQ:DORM) rating on Thursday, July 6. Jefferies has “Hold” rating and $8500 target. The company was maintained on Friday, October 27 by Jefferies. The stock has “Neutral” rating by B. Riley & Co on Thursday, February 18. Barrington Research initiated the shares of DORM in report on Wednesday, October 14 with “Outperform” rating. The stock has “Hold” rating by Jefferies on Tuesday, October 20. FBR Capital downgraded the shares of DORM in report on Thursday, February 23 to “Mkt Perform” rating. Jefferies maintained the stock with “Hold” rating in Wednesday, October 18 report.

Since August 14, 2017, it had 0 insider buys, and 1 sale for $134,676 activity. LEDERER PAUL R also sold $134,676 worth of Dorman Products, Inc. (NASDAQ:DORM) on Monday, August 14.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 0.01, from 1.23 in 2017Q2. It fall, as 27 investors sold DORM shares while 59 reduced holdings. 27 funds opened positions while 78 raised stakes. 25.22 million shares or 0.25% less from 25.28 million shares in 2017Q2 were reported. Comerica State Bank, Michigan-based fund reported 38,799 shares. Parametric Associates Limited Liability Corp has invested 0.01% in Dorman Products, Inc. (NASDAQ:DORM). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Dorman Products, Inc. (NASDAQ:DORM). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest reported 47,740 shares. 11,517 are owned by Wcm Investment Ca. Pnc Financial Grp holds 0.04% or 570,104 shares in its portfolio. Thrivent Financial For Lutherans stated it has 0% of its portfolio in Dorman Products, Inc. (NASDAQ:DORM). First Republic Investment Management stated it has 0% in Dorman Products, Inc. (NASDAQ:DORM). Rice Hall James & Assocs Limited Liability accumulated 207,042 shares or 0.66% of the stock. Delta Asset Lc Tn holds 0% or 10 shares. Regions Financial reported 7,389 shares. Contravisory Investment Management holds 16 shares. Atria Invs Ltd Limited Liability Company owns 6,140 shares. Bb&T owns 3,283 shares. Profund Advsr Ltd Liability Company has 0.01% invested in Dorman Products, Inc. (NASDAQ:DORM) for 3,734 shares.

Columbia Wanger Asset Management Llc decreased Hamilton Lane Inc stake by 31,811 shares to 391,657 valued at $10.52 million in 2017Q3. It also reduced Wageworks Inc (NYSE:WAGE) stake by 722,339 shares and now owns 146,888 shares. Q2 Holdings Inc (NYSE:QTWO) was reduced too.

Among 3 analysts covering Alimera Sciences (NASDAQ:ALIM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alimera Sciences had 13 analyst reports since August 12, 2015 according to SRatingsIntel. On Tuesday, July 11 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Friday, August 4. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, August 12. On Wednesday, November 22 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Friday, October 27. As per Tuesday, January 19, the company rating was maintained by Cantor Fitzgerald. The rating was maintained by H.C. Wainwright on Wednesday, August 30 with “Buy”. The firm earned “Buy” rating on Tuesday, July 11 by Cowen & Co. The stock has “Outperform” rating by Cowen & Co on Friday, September 16. The rating was maintained by Cowen & Co with “Buy” on Thursday, August 3.

Investors sentiment increased to 1.64 in Q3 2017. Its up 0.57, from 1.07 in 2017Q2. It is positive, as 4 investors sold ALIM shares while 7 reduced holdings. 8 funds opened positions while 10 raised stakes. 28.40 million shares or 11.41% more from 25.49 million shares in 2017Q2 were reported. Savings Bank Of Montreal Can reported 500 shares. Royal Bank & Trust Of Canada stated it has 8 shares or 0% of all its holdings. Knott David M holds 0.11% in Alimera Sciences, Inc. (NASDAQ:ALIM) or 199,000 shares. Armistice Ltd Company reported 1% stake. Jw Asset Mngmt Ltd accumulated 966,000 shares or 0.96% of the stock. Bnp Paribas Arbitrage Sa invested in 0% or 5 shares. Moreover, Jpmorgan Chase & has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 27,500 shares. Two Sigma Ltd, New York-based fund reported 12,870 shares. Goldman Sachs Grp owns 118,859 shares or 0% of their US portfolio. Blackrock Inc, New York-based fund reported 201,806 shares. Bridgeway Management stated it has 0.01% in Alimera Sciences, Inc. (NASDAQ:ALIM). Valley Natl Advisers Incorporated invested 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Orbimed Advsr Ltd Liability Corporation invested in 0% or 250,000 shares. Guggenheim Cap Lc has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Barclays Public Ltd stated it has 0% in Alimera Sciences, Inc. (NASDAQ:ALIM).

Armistice Capital Llc decreased Momenta Pharmaceuticals Inc (NASDAQ:MNTA) stake by 688,000 shares to 132,000 valued at $2.44 million in 2017Q3. It also reduced Campbell Soup Co (NYSE:CPB) stake by 184,000 shares and now owns 296,000 shares. Madrigal Pharmaceuticals Inc was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>